![]() Major treatment-resistant depression treatment players frequently announce significant business decisions that favor or negatively impact the market. Important Business-related Announcements by Key Players to Influence Market Dynamics The European market will grow at a significant CAGR during the projected period due to the increasing launch of new drugs to treat the disorder in the region. The growth is attributed to the rising patient population suffering from treatment-resistant depressive disorder in the region.Įurope held the second-largest treatment-resistant depression treatment market share in 2022. North America accounted for USD 0.79 Billion in 2022 and is estimated to dominate the treatment-resistant depression treatment market during the forecast period. Growing Patient Population to Boost Market Growth in North America In addition to placing a tremendous burden on social and healthcare resources, the prevalence is linked to disproportionate healthcare costs with large direct and indirect costs, hampering market growth. The demand for the disease's therapy has increased as this medical condition's prevalence has increased. TRD happens when a person hasn't reacted to two separate antidepressants or has not taken them for a sufficient amount of time, typically six weeks. One of the most important factors contributing to the treatment-resistant depression treatment market growth is the rise in the prevalence of this behavioral illness. Growing Prevalence of Treatment-Resistant Depression Worldwide to Drive Market Growth Quick Buy - Treatment-Resistant Depression Treatment Market Research Report: Geographically, the market is studied across North America, Europe, Asia Pacific, and Rest of the World.Įurope (Germany, U.K., France, Italy, Spain, and the Rest of Europe)Īsia Pacific (China, India, Japan, Australia, and the Rest of Asia Pacific) The growth is attributed to the increasing investment in healthcare infrastructure by the global public sector in emerging countries. The hospital pharmacies segment dominated the market in 2022 and is expected to grow at a significant CAGR during the forecast period. Rising Public Sector Investment in Healthcare Infrastructure to Drive Segment Growthīased on distribution channel, the treatment-resistant depression treatment market is classified into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The growth is attributed to the increasing demand for antidepressant drugs due to the rising occurrence of treatment-resistant depression. The antidepressants segment is expected to hold the dominant market share during the forecast period. Rising Demand for Antidepressant Drugs to Drive Segment Growthīy drug type, the treatment-resistant depression treatment market is segmented into N-methyl-D-aspartate (NMDA), antidepressants, antipsychotics, and others. (Otsuka Holdings Co., Ltd.) (Japan)īy Drug Type, Distribution Channel, and Geography Lundbeck A/S (Denmark), Sandoz International GmbH (Novartis AG) (Germany), Par Pharmaceutical (Endo International plc) (India), Otsuka Pharmaceutical Co., Ltd. (U.S.), Janssen Global Services, LLC (Johnson & Johnson Services, Inc.) (Belgium), AbbVie Inc. List of Key Players Present in the Report :Įli Lilly and Company (U.S.), GlaxoSmithKline (U.K.), Pfizer Inc. The expansion can be attributed to the increasing healthcare expenditures and the growing prevalence of mood disorders. In 2022, North America spearheaded the market, generating a revenue of USD 0.94 billion, and is poised to maintain its dominant position throughout the forecast period. ![]() The escalating prevalence of treatment-resistant depression stands out as a significant factor contributing to the market's growth. Treatment-resistant depression (TRD) occurs after inadequate response to around two antidepressants during the treatment process. May 2022 – Compass Pathways presented positive Phase IIb study data of COMP360 psilocybin therapy for treatment-resistant depression treatment at the American Psychiatric Association annual meeting in New Orleans, the U.S. The disorder is associated with melancholic clinical features, abnormal neural activity, bipolarity, inflammatory system activation, neurotransmitter dysfunction, and high traumatic load.įortune Business Insights™ mentioned this in a report titled “Treatment-Resistance Depression Treatment Market, 2023-2030.” 11, 2023 (GLOBE NEWSWIRE) - The treatment-resistant depression treatment market size is projected to grow from USD 1.95 billion in 2023 to USD 4.06 billion by 2030, exhibiting a CAGR of 11.0% during the forecast period. Treatment-Resistant Depression Treatment Market Forecasts, 2023-2030
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |